TERZAH HORTON to Adolescent
This is a "connection" page, showing publications TERZAH HORTON has written about Adolescent.
Connection Strength
0.440
-
Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group. Br J Haematol. 2019 07; 186(2):274-285.
Score: 0.042
-
Recurrent Patterns of Protein Expression Signatures in Pediatric Acute Lymphoblastic Leukemia: Recognition and Therapeutic Guidance. Mol Cancer Res. 2018 08; 16(8):1263-1274.
Score: 0.040
-
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Oct; 61(10):1754-60.
Score: 0.030
-
Children are not large mice. Eur J Haematol. 2013 Jun; 90(6):535.
Score: 0.028
-
A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Apr; 50(4):788-92.
Score: 0.020
-
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol. 2007 Nov 01; 25(31):4922-8.
Score: 0.019
-
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res. 2007 Mar 01; 13(5):1516-22.
Score: 0.018
-
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006 Jul; 58(1):13-23.
Score: 0.017
-
Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study. Clin Cancer Res. 2005 Mar 01; 11(5):1884-9.
Score: 0.016
-
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231. Blood. 2024 05 16; 143(20):2053-2058.
Score: 0.015
-
Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712. Pediatr Blood Cancer. 2023 Dec; 70(12):e30672.
Score: 0.014
-
Case series of thrombotic thrombocytopenic purpura in children and adolescents. J Pediatr Hematol Oncol. 2003 Apr; 25(4):336-9.
Score: 0.014
-
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. N Engl J Med. 2022 11 03; 387(18):1649-1660.
Score: 0.014
-
Comparison of the blood, bone marrow, and cerebrospinal fluid metabolomes in children with b-cell acute lymphoblastic leukemia. Sci Rep. 2021 10 04; 11(1):19613.
Score: 0.013
-
Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. Blood Adv. 2019 12 23; 3(24):4215-4227.
Score: 0.011
-
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial. Lancet Oncol. 2018 09; 19(9):1229-1238.
Score: 0.010
-
Recognition of Recurrent Protein Expression Patterns in Pediatric Acute Myeloid Leukemia Identified New Therapeutic Targets. Mol Cancer Res. 2018 08; 16(8):1275-1286.
Score: 0.010
-
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018 03 01; 131(9):995-999.
Score: 0.010
-
Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group. Pediatr Hematol Oncol. 2017 Sep - Oct; 34(6-7):355-364.
Score: 0.010
-
Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica. 2017 09; 102(9):e340-e343.
Score: 0.009
-
Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range. J Clin Pharmacol. 2017 09; 57(9):1183-1193.
Score: 0.009
-
Ethnic disparities relative to disease features and outcomes in children with acute myeloid leukemia. Pediatr Blood Cancer. 2017 Sep; 64(9).
Score: 0.009
-
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. J Hematol Oncol. 2016 09 06; 9(1):82.
Score: 0.009
-
A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma. 2016 07; 57(7):1567-74.
Score: 0.008
-
AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Cancer. 2014 Aug 15; 120(16):2482-9.
Score: 0.008
-
Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica. 2013 Dec; 98(12):1896-904.
Score: 0.007
-
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer. 2013 Sep; 60(9):1452-7.
Score: 0.007
-
A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Pediatr Blood Cancer. 2013 Mar; 60(3):390-5.
Score: 0.007
-
Pediatric Hodgkin lymphoma: are we over-scanning our patients? Pediatr Hematol Oncol. 2012 Aug; 29(5):415-23.
Score: 0.007
-
Severe neurologic side effects in patients being treated for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2009 May; 52(5):621-5.
Score: 0.005
-
Outcomes for children with gallbladder abnormalities and sickle cell disease. J Pediatr. 2004 Nov; 145(5):617-21.
Score: 0.004